La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

DexCom Croissance future

Future contrôle des critères 4/6

DexCom devrait augmenter ses bénéfices et son chiffre d'affaires de 16.7% et de 13.5% par an respectivement. Le BPA devrait croître de de 15.9% par an. Le rendement des capitaux propres devrait être 26.1% dans 3 ans.

Informations clés

16.7%

Taux de croissance des bénéfices

15.9%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.4%
Taux de croissance des recettes	13.5%
Rendement futur des capitaux propres	26.1%
Couverture par les analystes	Good
Dernière mise à jour	16 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Nov 25

Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

Oct 21

Dexcom launches G7 glucose monitoring system in parts of Europe, Asia

Oct 04

What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

Sep 24

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:DXCM - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	5,424	996	1,101	1,409	19
12/31/2025	4,653	813	852	1,170	24
12/31/2024	4,012	670	658	1,008	23
6/30/2024	3,935	667	666	891	N/A
3/31/2024	3,802	639	584	802	N/A
12/31/2023	3,622	542	512	749	N/A
9/30/2023	3,403	377	500	747	N/A
6/30/2023	3,198	358	466	771	N/A
3/31/2023	3,023	293	416	754	N/A
12/31/2022	2,910	341	305	670	N/A
9/30/2022	2,793	244	261	643	N/A
6/30/2022	2,673	230	216	597	N/A
3/31/2022	2,572	258	95	486	N/A
12/31/2021	2,449	217	53	443	N/A
9/30/2021	2,319	577	140	509	N/A
6/30/2021	2,170	562	101	409	N/A
3/31/2021	2,027	530	236	502	N/A
12/31/2020	1,927	550	277	476	N/A
9/30/2020	1,821	231	264	447	N/A
6/30/2020	1,716	205	209	394	N/A
3/31/2020	1,601	148	131	305	N/A
12/31/2019	1,476	101	135	315	N/A
9/30/2019	1,351	-171	51	205	N/A
6/30/2019	1,222	-170	39	167	N/A
3/31/2019	1,128	-130	53	144	N/A
12/31/2018	1,032	-127	56	123	N/A
9/30/2018	915	43	64	131	N/A
6/30/2018	833	-5	53	110	N/A
3/31/2018	761	-33	N/A	83	N/A
12/31/2017	719	-50	N/A	92	N/A
9/30/2017	669	-48	N/A	64	N/A
6/30/2017	633	-65	N/A	51	N/A
3/31/2017	599	-88	N/A	57	N/A
12/31/2016	573	-66	N/A	56	N/A
9/30/2016	533	-57	N/A	54	N/A
6/30/2016	490	-80	N/A	49	N/A
3/31/2016	445	-64	N/A	45	N/A
12/31/2015	402	-58	N/A	49	N/A
9/30/2015	356	-58	N/A	46	N/A
6/30/2015	319	-20	N/A	40	N/A
3/31/2015	285	-23	N/A	29	N/A
12/31/2014	259	-22	N/A	24	N/A
9/30/2014	227	-26	N/A	20	N/A
6/30/2014	201	-27	N/A	10	N/A
3/31/2014	178	-31	N/A	5	N/A
12/31/2013	160	-30	N/A	2	N/A
9/30/2013	142	-36	N/A	-13	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de DXCM ( 16.7% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de DXCM ( 16.7% par an) devraient croître plus rapidement que le marché US ( 15.1% par an).

Croissance élevée des bénéfices: Les bénéfices de DXCM devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de DXCM ( 13.5% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de DXCM ( 13.5% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de DXCM devrait être élevé dans 3 ans ( 26.1 %)

DexCom Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

DexCom, Inc. Updates Earnings Guidance for the Year 2024

DexCom, Inc. Provides Earnings Guidance for the Year 2024

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

DexCom, Inc. Updates Earnings Guidance for the Year 2025

Recent updates

DexCom Q2 Earnings: Traditional Market Overreaction

Investor sentiment deteriorates as stock falls 37%

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 41% undervalued after recent price drop

Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

DexCom, Inc. Updates Earnings Guidance for the Year 2024

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $750 million worth of its shares.

Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

DexCom, Inc. to Report Q2, 2024 Results on Jul 25, 2024

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States

Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Now 22% overvalued after recent price rise

Dexcom: Positive Catalysts Ahead To Support Growth

If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

DexCom: Attractive Discount After Strong Earnings Results

DexCom, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

DexCom, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

DexCom, Inc., Annual General Meeting, May 22, 2024

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Now 24% overvalued after recent price rise

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Executive Chairman recently sold US$4.0m worth of stock

Executive Chairman notifies of intention to sell stock

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Executive VP notifies of intention to sell stock

DexCom: A Wealth Compounder In Healthcare

Full year 2023 earnings: EPS exceeds analyst expectations

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Executive Chairman recently sold US$4.6m worth of stock

DexCom: Stelo Stellar Outlook

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Insufficient new directors

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

DexCom, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Dexcom, Inc. Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System with Unmatched Accuracy Coming to Canadians

DexCom, Inc. Updates Earnings Guidance for the Year 2025

DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet